1.24
-0.10 (-7.46%)
Penutupan Terdahulu | 1.34 |
Buka | 1.31 |
Jumlah Dagangan | 2,304,562 |
Purata Dagangan (3B) | 1,810,475 |
Modal Pasaran | 364,613,344 |
Harga / Pendapatan (P/E Ke hadapan) | 9.14 |
Harga / Jualan (P/S) | 91.06 |
Harga / Buku (P/B) | 10.19 |
Julat 52 Minggu | |
Tarikh Pendapatan | 12 May 2025 - 16 May 2025 |
Margin Operasi (TTM) | -1,910.67% |
EPS Cair (TTM) | -0.470 |
Pertumbuhan Hasil Suku Tahunan (YOY) | -3.10% |
Jumlah Hutang/Ekuiti (D/E MRQ) | 14.29% |
Nisbah Semasa (MRQ) | 4.76 |
Aliran Tunai Operasi (OCF TTM) | -68.17 M |
Aliran Tunai Bebas Leveraj (LFCF TTM) | -53.05 M |
Pulangan Atas Aset (ROA TTM) | -39.95% |
Pulangan Atas Ekuiti (ROE TTM) | -160.80% |
Arah Aliran Pasaran
Jangka Pendek | Jangka Sederhana | ||
Industri | Biotechnology (US) | Bercampur | Bercampur |
Biotechnology (Global) | Bercampur | Bercampur | |
Stok | Precigen, Inc. | Menaik | Menurun |
AISkor Stockmoo
Konsensus Penganalisis | 5.0 |
Aktiviti Orang Dalam | NA |
Volatiliti Harga | -2.0 |
Purata Bergerak Teknikal | 0.0 |
Osilator Teknikal | -0.5 |
Purata | 0.63 |
Precigen Inc is a biotechnology company that develops synthetic biology solutions. The company designs build and regulate gene programs. Its technologies are broadly applicable across a wide range of diverse end markets. Intrexon's business model is to commercialize its technologies through exclusive channel collaborations with collaborators that have specific industry expertise, development resources, and sales and marketing capabilities, in order to bring new and improved products and processes to market. Its reportable segments are Biopharmaceuticals and Exemplar. The company's collaborators provide compensation through technology access fees, royalties, milestones, and reimbursement of certain costs. |
|
Sektor | Healthcare |
Industri | Biotechnology |
Gaya Pelaburan | Small Value |
% Dimiliki oleh Orang Dalam | 9.97% |
% Dimiliki oleh Institusi | 66.12% |
Pemilikan
Nama | Tarikh | Syer Dipegang |
---|---|---|
Iridian Asset Management Llc/Ct | 31 Dec 2024 | 5,241,922 |
Lexaurum Advisors, Llc | 31 Dec 2024 | 691,544 |
Julat 52 Minggu | ||
Julat Harga Sasaran | ||
Tinggi | 6.00 (HC Wainwright & Co., 383.87%) | Beli |
6.00 (Citizens Capital Markets, 383.87%) | Beli | |
Median | 6.00 (383.87%) | |
Rendah | 5.00 (JMP Securities, 303.23%) | Beli |
Purata | 5.67 (357.26%) | |
Jumlah | 3 Beli | |
Harga Purata @ Panggilan | 1.56 |
Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
---|---|---|---|---|
Citizens Capital Markets | 20 Mar 2025 | 6.00 (383.87%) | Beli | 1.80 |
HC Wainwright & Co. | 20 Mar 2025 | 6.00 (383.87%) | Beli | 1.80 |
23 Jan 2025 | 6.00 (383.87%) | Beli | 1.34 | |
JMP Securities | 14 Jan 2025 | 5.00 (303.23%) | Beli | 1.09 |
Tiada data dalam julat masa ini.
Tarikh | Jenis | Butiran |
---|---|---|
19 Mar 2025 | Pengumuman | Precigen Reports Full Year 2024 Financial Results and Business Updates |
25 Feb 2025 | Pengumuman | FDA Grants Priority Review to Precigen's BLA for PRGN-2012 for the Treatment of Adults with Recurrent Respiratory Papillomatosis with PDUFA Target Action Date Set for August 27, 2025 |
13 Jan 2025 | Pengumuman | Precigen to Present Plans for Realizing Commercial Vision for PRGN-2012 at the 43rd Annual J.P. Morgan Healthcare Conference |
09 Jan 2025 | Pengumuman | Precigen to Present at the 43rd Annual J.P. Morgan Healthcare Conference |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
Keuntungan Nyata | - |
Keuntungan Tidak Nyata | - |
Dividen Diterima 2025 | - |
Jumlah Untung | - |
Pulangan Purata | - |
Kuantiti (Beli) | - |
Purata Harga (Beli) | - |
Kuantiti (Jual) | - |
Purata Harga (Jual) | - |